Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01484678|
Recruitment Status : Recruiting
First Posted : December 2, 2011
Last Update Posted : December 31, 2018
The purpose of this research study is to determine the potential of magnetic resonance imaging to monitor disease progression and to serve as an objective outcome measure for clinical trials in Duchenne Muscular Dystrophy (DMD). The investigators also hope to learn more about the changes that occur in muscles of the lower leg and arm in boys with DMD.
The investigators will compare the muscles of ambulatory or non-ambulatory boys with DMD with muscles of healthy children of the same age and monitor disease progression in boys with DMD over a 5-10 year period. The amount of muscle damage and fat that the investigators measure will also be related to performance in daily activities, such as walking and the loss of muscle strength. In a small group of subjects the investigators will also assess the effect of corticosteroid drugs on the muscle measurements.
|Condition or disease|
|Duchenne Muscular Dystrophy|
The overall objective of this proposal is to validate the potential of noninvasive magnetic resonance imaging (MRI) and spectroscopy (MRS) to monitor disease progression and to serve as an outcome measure for clinical trials in Duchenne muscular dystrophy (DMD). DMD is one of the most devastating genetically linked neuromuscular diseases and is characterized by the absence of dystrophin, resulting in progressive muscle weakness, loss of walking ability and premature death. Despite the poor prognosis for patients with muscular dystrophy, therapeutic interventions have been lacking, and outcome measures for clinical trials have been limited to measures of muscle function, serum biomarkers of muscle breakdown and invasive muscle biopsies. Additional quantitative outcome measures that are noninvasive and sensitive to changes in muscle structure and composition are needed to facilitate the rapid translation of promising new interventions from preclinical studies to clinical trials. As such, this proposal targets the development and validation of magnetic resonance as a noninvasive biomarker of disease progression in muscular dystrophy. Using a multi-site research design this study will examine the intramuscular lipid content, muscle damage/inflammation and contractile area in the lower extremity and/or upper extremity muscles of 200 ambulatory or non-ambulatory boys with DMD and 100 healthy age matched boys using a combination of MRI and MRS technologies. In order to assess the sensitivity of each MR measure to disease progression, all boys with DMD will be reevaluated in yearly or 6 month intervals. In addition, the investigators will correlate changes in MR measures with standard measures of disease progression, such as loss in muscle strength and functional ability. Using MRI/MRS the investigators will also examine the effect of initiating corticosteroid treatment on skeletal muscle characteristics and composition. Finally, the investigators will deposit immortalized fibroblasts from carefully characterized DMD boys participating in this study in established tissue repositories.
The investigators anticipate that the MR techniques developed and validated in this proposal will be suitable for clinical trials in a wide range of muscular dystrophies and other neuromuscular diseases. In addition, MR characterization may serve as a powerful tool to further advance our understanding of the pathogenesis of muscular dystrophy and help guide the design of future trials.
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy; The Relationship Between Genomic Variants And MRI/MRS Markers In DMD|
|Study Start Date :||May 2010|
|Estimated Primary Completion Date :||April 2020|
|Estimated Study Completion Date :||April 2020|
Age Matched Controls
Age matched non-affected (non-DMD) boys
Boys with DMD
This group will include ambulatory and non-ambulatory boys with Duchenne Muscular Dystrophy ranging form 5-18 years old.
- Change from baseline in intramuscular lipid up to 5-10 years [ Time Frame: Change in baseline up to 5-10 years ]MR measures of intramuscular lipid will be measured in yearly intervals for a period up to 5-10 years.
- Change from baseline in muscle T2 up to 3 months [ Time Frame: Change in baseline up to 3 months ]In a subgroup of subjects the effect of corticosteroids on muscle T2 will be measured at 3 and 6 months. Muscle T2 is a noninvasive marker of muscle damage/inflammation and will be measured using MR. This substudy requires its own Primary and Secondary Outcome measures.
- Change from baseline in muscle T2 up to 5-10 years [ Time Frame: Change in baseline up to 5-10 years ]
Muscle T2 will be measured in the lower extremity and/or upper extremity muscles using MR at yearly intervals up to 5-10 years.
We will report the change for each year interval.
- Change from baseline in muscle contractile area up to 5-10 years [ Time Frame: change in baseline up to 5-10 years ]Muscle contractile area will be measured in the lower extremity and/or upper extremity muscles using MR at yearly intervals up to 5 years. We will report the change for each year interval.
- Change from baseline in muscle T2 at 6 months [ Time Frame: Change in baseline up to 6 months ]In a subgroup of subjects the effect of corticosteroids on muscle T2 will be measured at 3 and 6 months. Muscle T2 is a noninvasive marker of muscle damage/inflammation and will be measured using MR. This substudy requires its own Primary and Secondary Outcome measures.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01484678
|Contact: Krista Vandenborne, PhDfirstname.lastname@example.org|
|Contact: Claudia Senesac, PhDemail@example.com|
|United States, Florida|
|University of Florida||Recruiting|
|Gainesville, Florida, United States, 32610|
|Contact: Krista Vandenborne, PhD 352-273-6100 firstname.lastname@example.org|
|Contact: Claudia Senesac, PhD 352-273-6453 email@example.com|
|Principal Investigator: Krista Vandenborne, PhD|
|United States, Oregon|
|Oregon Health and Science University||Recruiting|
|Portland, Oregon, United States, 97239|
|Contact: William Rooney, PhD 503-418-1532 firstname.lastname@example.org|
|Contact: Laura McMahon 503-418-1540 email@example.com|
|Principal Investigator: Bill Rooney, PhD|
|United States, Pennsylvania|
|Children's Hospital of Philadelphia||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Gihan Tennekoon, MD 215-590-1710 firstname.lastname@example.org|
|Contact: Michele Toms 215-590-7727 email@example.com|
|Principal Investigator: Gihan Tennekoon, MD|
|Principal Investigator:||Gihan Tennekoon, MD||Children's Hospital of Philadelphia|
|Principal Investigator:||William Rooney, PhD||Oregan Health and Science University|
|Principal Investigator:||H. Lee Sweeney, PhD||University of Florida|
|Principal Investigator:||Krista Vandenborne, PhD||University of Florida|